GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Glaukos Corp (NYSE:GKOS) » Definitions » Interest Coverage
中文

Glaukos (Glaukos) Interest Coverage : 0 (At Loss) (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Glaukos Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Glaukos's Operating Income for the three months ended in Dec. 2023 was $-38.6 Mil. Glaukos's Interest Expense for the three months ended in Dec. 2023 was $-3.4 Mil. did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for Glaukos's Interest Coverage or its related term are showing as below:


GKOS's Interest Coverage is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 19.77
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Glaukos Interest Coverage Historical Data

The historical data trend for Glaukos's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Glaukos Interest Coverage Chart

Glaukos Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Interest Coverage
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Glaukos Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Glaukos's Interest Coverage

For the Medical Devices subindustry, Glaukos's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Glaukos's Interest Coverage Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Glaukos's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Glaukos's Interest Coverage falls into.



Glaukos Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Glaukos's Interest Coverage for the fiscal year that ended in Dec. 2023 is calculated as

Here, for the fiscal year that ended in Dec. 2023, Glaukos's Interest Expense was $-13.6 Mil. Its Operating Income was $-128.7 Mil. And its Long-Term Debt & Capital Lease Obligation was $383.7 Mil.

Glaukos did not have earnings to cover the interest expense.

Glaukos's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Here, for the three months ended in Dec. 2023, Glaukos's Interest Expense was $-3.4 Mil. Its Operating Income was $-38.6 Mil. And its Long-Term Debt & Capital Lease Obligation was $383.7 Mil.

Glaukos did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


Glaukos  (NYSE:GKOS) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


Glaukos Interest Coverage Related Terms

Thank you for viewing the detailed overview of Glaukos's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Glaukos (Glaukos) Business Description

Traded in Other Exchanges
Address
One Glaukos Way, Aliso Viejo, CA, USA, 92656
Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. Its product pipeline also consists of an iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure.
Executives
Alex R. Thurman officer: SVP & Chief Financial Officer C/O GLAUKOS CORPORATION, 229 AVENIDA FABRICANTE, SAN CLEMENTE CA 92672
Joseph E Gilliam officer: CFO, SVP Corporate Development C/O GLAUKOS CORPORATION, 229 AVENIDA FABRICANTE, SAN CLEMENTE CA 92677
Thomas William Burns director, 10 percent owner, officer: Chief Executive Officer C/O GLAUKOS CORPORATION,, 26051 MERIT CIRCLE, SUITE 103, LAGUNA HILLS CA 92653
Marc Stapley director 9885 TOWNE CENTRE DRIVE, SAN DIEGO CA 92121
Gilbert H Kliman director C/O INTERWEST PARTNERS, 467 FIRST STREET SUITE 201, LOS ALTOS CA 94022
Tomas Navratil officer: Chief Development Officer C/O GLAUKOS CORPORATION, 229 AVENIDA FABRICANTE, SAN CLEMENTE CA 92672
Leana Wen director C/O GLAUKOS CORPORATION, 229 AVENIDA FABRICANTE, SAN CLEMENTE CA 92672
Denice Torres director 3 RABBIT RUN DRIVE, NEW HOPE PA 18938
Chris M. Calcaterra officer: Chief Commercial Officer C/O GLAUKOS CORPORATION, 26051 MERIT CIRCLE, SUITE 103, LAGUNA HILLS CA 92653
Link William J Phd director, 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Jonathan Silverstein director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Advisors Llc director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Richard L Harrison officer: Treasurer, CFO & Secretary 26051 MERIT CIRCLE, SUITE 103, LAGUNA HILLS CA 92653
Samuel D Isaly director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Capital Gp Iii Llc director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022

Glaukos (Glaukos) Headlines

From GuruFocus

Should Investors Worry About Glaukos Corp's Insider Sells?

By GuruFocus Research GuruFocus Editor 05-21-2023

Insider Alert: An Insider Just Sold Glaukos Corp Shares

By GuruFocus Research GuruFocus Editor 05-19-2023

Insider Alert: An Insider Just Sold Glaukos Corp Shares

By GuruFocus Research GuruFocus Editor 05-20-2023

INTERWEST VENTURE MANAGEMENT CO's Top 5 Sells of the 4th Quarter

By GuruFocus Research GuruFocus Editor 01-31-2023